Reducing the Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus-Associated Oropharyngeal Carcinoma Being Treated With Primary Chemoradiotherapy at Memorial Sloan Kettering Cancer Center.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cancer Care Facilities
/ statistics & numerical data
Chemoradiotherapy
/ methods
Cisplatin
/ therapeutic use
Cyclin-Dependent Kinase Inhibitor p16
/ analysis
Humans
Neoplasm Staging
Oropharyngeal Neoplasms
/ diagnostic imaging
Papillomaviridae
/ genetics
Papillomavirus Infections
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Practice Guidelines as Topic
RNA, Viral
/ isolation & purification
Radiation Tolerance
Radiotherapy Dosage
/ standards
Treatment Outcome
Journal
Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
05
10
2018
revised:
17
10
2018
accepted:
29
10
2018
pubmed:
18
11
2018
medline:
6
4
2019
entrez:
17
11
2018
Statut:
ppublish
Résumé
Data on the biology and radiosensitivity of human papillomavirus-related cancers have led many expert radiation oncologists to decrease the radiation dose to target areas in selected situations. At Memorial Sloan Kettering Cancer Center, we have altered our radiation guidelines to allow substantial dose reduction to elective treatment regions and to omit radiation completely in other regions that have historically been included in the elective treatment volume. Here we summarize our current dose prescriptions and briefly explain the rationale behind these choices, which we anticipate will change when additional data mature. These recommendations are based on the American Joint Committee on Cancer seventh edition TNM Staging System and applicable only to patients who receive concurrent platinum-based chemotherapy and in whom both p16 immunohistochemistry and human papillomavirus RNA in situ hybridization tests are positive.
Identifiants
pubmed: 30445229
pii: S1879-8500(18)30316-3
doi: 10.1016/j.prro.2018.10.015
pii:
doi:
Substances chimiques
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
RNA, Viral
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-101Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.